University Health Network, Toronto
Data updated
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
Academic Research
0 papersPublished Papers
0
Trial Involvement
8
Distinct Focus Topics
0
Latest Publication
Unknown
Entity type: Research Centre / Institute
Network Scope
Hospital-network model with affiliated research institutes and multi-program collaborations.
Connected Research Organizations
Collaboration Notes
Large academic health network with university-linked research programs, including psychiatric and translational collaborations.
Clinical Care Delivery Snapshot
Health Systems & HospitalsProvider Model
Health System / Hospital Program
Organization Status
Unknown
Psychedelic Services
Unknown
Service Coverage
Global
Service Profile
Care Settings
Payer Models
Non-Psychedelic Service Mix
Unknown
Care Delivery Notes
Backfilled profile for existing L2 clinical care delivery stakeholder.
Research journey
Built from the 7 trials University Health Network, Toronto has sponsored, placed at the date each one started.
Quick Facts
- Type
- Other
- HQ
- Canada
- Website
- Visit
Research Landscape
What the registered trials University Health Network, Toronto sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of August 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 8 University Health Network, Toronto trials Blossom tracks. Orange marks trials recruiting or opening.
- Recruiting or opening
- 450%
- Underway, not recruiting
- 225%
- Completed
- 113%
- Unknown / other
- 113%
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Sponsored Trials
7Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer (PEARL-C1)
- Start Date
- Compounds
- Psilocybin
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression (Psilo-BD)
- Start Date
- Compounds
- Psilocybin
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
- Start Date
- Compounds
- Psilocybin
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)
- Start Date
- Compounds
- Psilocybin
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial (Ket-CBT)
- Start Date
- Compounds
- Ketamine
Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches
- Start Date
- Compounds
- Ketamine, Placebo
Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
- Start Date
- Compounds
- Ketamine
Where this pipeline sits in the field
University Health Network, Toronto runs late-stage trials that Blossom ranks by how soon a catalyst is expected, alongside every other Phase 2 and Phase 3 study in the field.
Collaborated Trials
1Recent activity
- StartedPsilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients W… (NCT07048743, psilocybin)
- StartedNeurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression (Psilo-BD) (NCT06506019, psilocybin)
- StartedPsilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced C… (NCT06416085, psilocybin)
- StartedPsilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of… (NCT06341426, psilocybin)
- Startedi-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controll… (NCT06480500, ketamine)
- StartedMulti-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches (NCT05306899, ketamine)
- CompletedStudy of Ketamine for Depression in Cancer Patients Receiving Palliative Care (NCT03410446, ketamine)
- StartedKetamine Versus Electroconvulsive Therapy in Depression (NCT03674671, ketamine)